SLS
HEALTHCARESELLAS Life Sciences Group Inc
$5.15+0.28 (+5.75%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving SLS Today?
No stock-specific AI insight has been generated for SLS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.36$6.14
$5.15
Fundamentals
Market Cap$910M
P/E Ratio—
EPS$-0.25
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume3.5M
Avg Volume (10D)—
Shares Outstanding184.5M
SLS News
20 articles- Inventiva Builds Up Leadership Team Ahead of Potential CommercializationYahoo Finance·Apr 22, 2026
- Wall Street Analysts Think SELLAS Life Sciences Group, Inc. (SLS) Could Surge 66.09%: Read This Before Placing a BetYahoo Finance·Apr 20, 2026
- SELLAS Life Sciences Group Inc. (SLS) Making Progress on Key Acute Myeloid Leukemia TreatmentYahoo Finance·Apr 14, 2026
- Solaris Secures EIA Technical Approval and Further Strengthens the Balance SheetYahoo Finance·Apr 9, 2026
- SELLAS Life Sciences (SLS) to Present SLS009 Data at AACR 2026Yahoo Finance·Mar 27, 2026
- All You Need to Know About SELLAS Life Sciences Group, Inc. (SLS) Rating Upgrade to BuyYahoo Finance·Mar 26, 2026
- Wall Street Analysts Believe SELLAS Life Sciences Group, Inc. (SLS) Could Rally 63.58%: Here's is How to TradeYahoo Finance·Mar 26, 2026
- Assessing SELLAS Life Sciences Group (SLS) Valuation After Its Sharp Recent Share Price RunYahoo Finance·Mar 22, 2026
- SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths247 Wall St·Mar 20, 2026
- SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 19, 2026
- SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR ConferenceYahoo Finance·Mar 17, 2026
- SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009Yahoo Finance·Mar 12, 2026
- SELLAS Life Sciences (SLS) Is Up 18.0% After Positive AML Trial Updates – What’s ChangedYahoo Finance·Mar 10, 2026
- Assessing SELLAS Life Sciences Group (SLS) Valuation After Recent Leukemia Trial UpdatesYahoo Finance·Mar 7, 2026
- A Look At SELLAS Life Sciences Group (SLS) Valuation After New IMPACT AML Clinical Study AgreementYahoo Finance·Jan 15, 2026
- SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into EuropeYahoo Finance·Jan 14, 2026
- SELLAS Life Sciences Group (SLS) Is Up 50.8% After REGAL Trial Nears Final OS Trigger - Has The Bull Case Changed?Yahoo Finance·Jan 6, 2026
- Social Buzz: Wallstreetbets Stocks Advance Premarket Monday; SELLAS Life Sciences Group, Chevron to Open HigherYahoo Finance·Jan 5, 2026
- SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)Yahoo Finance·Dec 29, 2025
- Assessing SELLAS Life Sciences Group (SLS) Valuation After Positive Leukemia Data and Supportive FDA DesignationsYahoo Finance·Dec 25, 2025
All 20 articles loaded
Price Data
Open$4.91
Previous Close$4.87
Day High$5.24
Day Low$4.90
52 Week High$6.14
52 Week Low$1.36
52-Week Range
$1.36$6.14
$5.15
Fundamentals
Market Cap$910M
P/E Ratio—
EPS$-0.25
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume3.5M
Avg Volume (10D)—
Shares Outstanding184.5M
About SELLAS Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications of cancer in the United States. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—